(Q45925622)

English

Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.

scientific article published on 17 July 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

5

object named as

James Jin

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

author name string

Karl Andersen

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

Myron H Weinberger

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

Christian M Constance

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

Mohammed A Ali

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

Margaret F Prescott

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

Deborah L Keefe

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

publication date

17 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

Journal of the Renin-Angiotensin-Aldosterone System

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

10

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

157-167

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Aliskiren: the first direct renin inhibitor for hypertension

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Are tirofiban and abciximab identical in efficacy?

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Renin inhibition

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Conformational changes in prorenin during renin inhibition in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

The renin rise with aliskiren: it's simply stoichiometry

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Aliskiren accumulates in Renin secretory granules and binds plasma prorenin

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342407

21 January 2018

Identifiers

10.1177/1470320309342407

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/19617271

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45925622&oldid=1576590234"